CAR T cells targeting B7H3 demonstrate potent preclinical activity against AML and ESCC

T cells engineered to express chimeric antigen receptors (CARs) are a promising modality to treat refractory cancers. CD19 CAR-T therapy has achieved remarkable responses in against B-cell lymphomas, however, challenges persist for acute myeloid leukemia (AML) and solid malignancies. B7H3 is an immune regulatory molecule that is highly expressed in various tumor cells. Its abnormal expression in acute AML and esophageal squamous cell carcinoma (ESCC) is closely related to tumor progression.

Citation:
Liu C, Zhao J, Zhang X, Gao C, ……. Wang T, Sun X, Chai Y, et al. CAR T cells targeting B7H3 demonstrate potent preclinical activity against AML and ESCC. Int Immunopharmacol. 2026;168.

Keywords:
Acute myeloid leukemia; B7H3; Cancer immunotherapy; Chimeric antigen receptor; Esophageal squamous cell carcinoma

Abstract:
T cells engineered to express chimeric antigen receptors (CARs) are a promising modality to treat refractory cancers. CD19 CAR-T therapy has achieved remarkable responses in against B-cell lymphomas, however, challenges persist for acute myeloid leukemia (AML) and solid malignancies. B7H3 is an immune regulatory molecule that is highly expressed in various tumor cells. Its abnormal expression in acute AML and esophageal squamous cell carcinoma (ESCC) is closely related to tumor progression.